University of Cambridge
Also known as: Addenbrookes | Addenbrookes Charitable Trust | Addenbrookes Hospital | Addenbrooke`s Hospital and University of Cambridge | Addenbrooke's Hospital, Cambridge | Addenbrooke's Hospital, Cambridge, UK | Addenbrookes Hospital, Cambridge, United Kingdom | Addenbrooke's Hospital, UK | Addenbrooke's Hospital University of Cambridge, UK | Addenbrookes Hosptal NHS Trust/ University of Cambridge | Addenbrookes NHS Trust | Addenbrooke's NHS Trust, Cambridge, United Kingdom | Adel Helmy | Arun Gupta | Bourn Hall Clinic, Bourn Hall, High Street, Bourn, Cambridge CB3 7TR | Breast Cancer Research Unit, University of Cambridge | Cambridge Biomedical Campus | Cambridge Centre for Brain Repair, Cambridge, UK | Cambridge Clinical Trials Unit | Cambridge Institute for Medical Research, Addenbrooke's Hospital | Cambridgeshire and Peterborough NHS Foundation Trust | Cambridge University | Cambridge University and Cambridge University Hospitals NHS Foundation Trust | Cambridge University Hospital | Cambridge University Hospital, Department of Neurosurgery | Cambridge University Hospitals | Cambridge University Hospitals NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | Cambridge University Hospitals NHS Foundation Trust (CAM) | Cambridge University Hospitals NHS Foundation Trust (joint Sponsor) | Cambridge University Hospitals NHS Foundation Trust & University of Cambridge | Cambridge University Hospitals NHS Foundation Trust/University of Cambridge | Cambridge University Hospitals, NHS Foundation Trust, University of Cambridge | Cambridge University Hospitals NHS Trust | Cambridge University, UK | Cambridge Unversity Hospitals NHS Foundation Trust; Unversity of Cambridge | CCTU | CCTU- Cancer Theme | CCTU-Core | Clinical Unit at Cambridge (Addenbrooks) | CRUK Cambridge Institute | CRUK Cambridge Institute and the University of Cambridge | CRUK Cambridge Institute, University of Cambridge | Department of Biological Anthropology, University of Cambridge | Department of Pathology University of Cambridge | Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Hills Road, CB2 0QQ Cambridge, UK | Institute of Metabolic Science, Hills Road, CB2 0QQ, Cambridge, UK | Lisa Bax | Lupus and Vasculitis Service, Addenbrooke's Hospital | MRC Cancer Unit.University of Cambridge. | MRC Mitochondrial Biology Unit | Rachel Jones | Simon C Pacey, MD | The University of Cambridge, Department of Oncology | The University of Cambridge (joint Sponsor) | University Department of Radiology, University of Cambridge, Addenbrooke's Hospital, Hills Road, CB2 0QQ Cambridge, UK | University of Cambridge | University of Cambridge, Addenbrooke's Hospital, UK | University of Cambridge; honorary contract with Cambridge University Hospitals NHS Foundation Trust | University of Cambridge, UK | Wellcome Trust-MRC Institute of Metabolic Science University of Cambridge
Highest phase reached
Phase 4
First clinical trial
Dec 31, 1991
Last known activity
Nov 30, 2025
Timeline
1200s
- Jan 1, 1209
University of Cambridge— Founded
Drugs by trial phase (256 distinct, 191 trials)
Phase 4 (39 own, 0 via acquisition)
Phase 3 (71 own, 0 via acquisition)
Phase 2 (86 own, 0 via acquisition)
Phase 1 (18 own, 0 via acquisition)
Other trials (42 own, 0 via acquisition)
Indications
Studied for
- Acute Coronary Syndrome
- Adenocarcinoma
- Adenoma, Islet Cell
- Alcoholism
- Anemia
- Anemia, Iron-Deficiency
- Aneurysm
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Atrial Fibrillation
- Autoimmune Diseases
- Barrett Esophagus
- Behcet Syndrome
- Blindness
- Bone Marrow Diseases
- Brain Injuries
- Brain Injuries, Traumatic
- Brain Neoplasms
- Breast Neoplasms
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell
- Cardio-Renal Syndrome
- Cardiotoxicity
- Cardiovascular Diseases
- Central Nervous System Neoplasms
- Cerebral Hemorrhage
- Colorectal Neoplasms
- Compulsive Behavior
- Compulsive Personality Disorder
- Coronary Artery Disease
- Cystadenocarcinoma, Serous
- Dementia
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Drug-Related Side Effects and Adverse Reactions
- Encephalitis
- Epilepsy
- Esophageal Neoplasms
- Essential Hypertension
- Familial Primary Pulmonary Hypertension
- Gastrointestinal Neoplasms
- Gaucher Disease
- Glioblastoma
- Glucose Intolerance
- Granulomatosis with Polyangiitis
- Hand-Foot Syndrome
- Heart Diseases
- Hemorrhage
- Hodgkin Disease
- Hyperalgesia
- Hypertension
- Infections
- Infertility
- Inflammation
- Inflammatory Bowel Diseases
- Intracranial Hypertension
- Ischemia
- Lung Diseases
- Lung Diseases, Interstitial
- Lung Diseases, Obstructive
- Lung Neoplasms
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Major Depressive Disorder
- Malaria
- Malignant Carcinoid Syndrome
- Melanoma
- Meningitis
- Mental Disorders
- Microscopic Polyangiitis
- Mucopolysaccharidoses
- Mucopolysaccharidosis II
- Mucositis
- Multiple Sclerosis
- Myocardial Ischemia
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Nausea
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Nephritis
- Nervous System Neoplasms
- Neuroendocrine Tumors
- Obsessive-Compulsive Disorder
- Osteoarthritis
- Overweight
- Pancreatic Neoplasms
- Parkinson Disease
- Peanut Hypersensitivity
- Postoperative Complications
Recent trials (50)
- NCT07157735Lead sponsorPhase 2Nov 30, 2025
- NCT07157735CollaboratorPhase 2Nov 30, 2025
- NCT07157735OfficialPhase 2Nov 30, 2025
- NCT07157735Sponsor investigatorPhase 2Nov 30, 2025
- NCT06778564CollaboratorPhase 3Apr 30, 2025
- NCT07002320CollaboratorPhase 1/Phase 2Apr 28, 2025
- NCT06630260CollaboratorPhase 1/Phase 2Nov 4, 2024
- NCT06630260CollaboratorPhase 1/Phase 2Nov 4, 2024
- NCT06632236CollaboratorPhase 1Oct 9, 2024
- NCT06632236CollaboratorPhase 1Oct 9, 2024
- NCT06452654CollaboratorPhase 4May 8, 2024
- NCT06336317CollaboratorPhase 4Apr 24, 2024
- NCT06114628CollaboratorPhase 2Dec 8, 2023
- NCT06188520OfficialPhase 1/Phase 2Dec 5, 2023
- NCT05991388Overall official - principal investigatorPhase 2/Phase 3Oct 31, 2023
Details
- Founded
- Cambridge, GB Jan 1, 1209
- Last known activity
- Nov 30, 2025